Regulatory mechanism of long noncoding RNA in the occurrence and development of leukemia: a review.

Tingting LI; Jinxuan Hong; Yun MA; Bincai Yang; Guoqing Wang; Song Wang; Jilong Chen; Xiaojuan Chi

Return

Regulatory mechanism of long noncoding RNA in the occurrence and development of leukemia: a review.

Author: Tingting LI ¹ ; Jinxuan HONG ¹ ; Yun MA ² ; Bincai YANG ¹ ; Guoqing WANG ¹ ; Song WANG ¹ ; Jilong CHEN ¹ ; Xiaojuan CHI ¹
Author Information

1. College of Animal Sciences (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou 350002, Fujian, China.
2. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
Publication Type:Review
Keywords: biomarker; diagnosis and prognosis; leukemia; long noncoding RNA; regulatory mechanisms
MeSH: Cell Proliferation; Humans; Leukemia/genetics*; MicroRNAs; Neoplasms; RNA, Long Noncoding/genetics*
From: Chinese Journal of Biotechnology 2021;37(11):3933-3944
CountryChina
Language:Chinese
Abstract: Long noncoding RNAs (lncRNAs) are a class of RNA molecules that are greater than 200 nt in length and do not have protein-coding capabilities or encode micropeptides only. LncRNAs are involved in the regulation of cell proliferation, differentiation, apoptosis and other biological processes, and are closely associated with the occurrence, recurrence and metastasis of a variety of malignant hematologic diseases. This article summarizes the function, regulatory mechanism and potential clinical application of lncRNAs in leukemia. In general, lncRNAs regulate the occurrence and development of leukemia and the multi-drug resistance in chemotherapy through epigenetic modification, ribosomal RNA transcription, competitive binding with miRNA, modulating glucose metabolic pathway, and activating tumor-related signaling pathway. Studies on lncRNAs provide new references for understanding the pathogenesis of leukemia, uncovering new prognostic markers and potential therapeutic targets, and addressing the problems of drug resistance and post-treatment recurrence in patients in clinical treatment of leukemia.